---
document_datetime: 2025-12-02 07:06:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sovrima.html
document_name: sovrima.html
version: success
processing_time: 0.0590078
conversion_datetime: 2025-12-26 20:26:56.290735
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sovrima

[RSS](/en/individual-human-medicine.xml/65414)

##### Refused

This medicine has been refused authorisation

idebenone Medicine Human Refused

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Sovrima](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 24 July 2008, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Sovrima 150 mg tablets, intended for the treatment of Friedreich's ataxia. The company that applied for authorisation is Santhera Pharmaceuticals (Deutschland) GmbH. The applicant requested a re-examination of the opinion. After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 20 November 2008.

Questions and answers on the recommendation for the refusal of the marketing authorization for Sovrima

English (EN) (36.71 KB - PDF)

**First published:** 21/11/2008

**Last updated:** 21/11/2008

[View](/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_en.pdf)

[Other languages (20)](#file-language-dropdown-384)

български (BG) (174.25 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_bg.pdf)

español (ES) (39.88 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_es.pdf)

čeština (CS) (122.2 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_cs.pdf)

dansk (DA) (37.71 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_da.pdf)

Deutsch (DE) (38.3 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_de.pdf)

eesti keel (ET) (36.57 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_et.pdf)

ελληνικά (EL) (166.89 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_el.pdf)

italiano (IT) (37.26 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_it.pdf)

latviešu valoda (LV) (121.45 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_lv.pdf)

lietuvių kalba (LT) (118.65 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_lt.pdf)

magyar (HU) (113.51 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_hu.pdf)

Malti (MT) (154.67 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_mt.pdf)

Nederlands (NL) (37.23 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_nl.pdf)

polski (PL) (124.19 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_pl.pdf)

português (PT) (37.64 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_pt.pdf)

română (RO) (133.27 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_ro.pdf)

slovenčina (SK) (150.4 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_sk.pdf)

slovenščina (SL) (113.3 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_sl.pdf)

Suomi (FI) (37.14 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_fi.pdf)

svenska (SV) (37.07 KB - PDF)

**First published:**

21/11/2008

**Last updated:**

21/11/2008

[View](/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_sv.pdf)

## Product details

Name of medicine Sovrima Active substance idebenone International non-proprietary name (INN) or common name idebenone Therapeutic area (MeSH) Friedreich Ataxia Anatomical therapeutic chemical (ATC) code N06BX13

### Pharmacotherapeutic group

Psychoanaleptics

## Application details

EMA product number EMEA/H/C/000908

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation applicant Centocor B.V. Opinion adopted 20/11/2008 Refusal of marketing authorisation 27/04/2009

## Assessment history

Sovrima : EPAR - Public assessment report

English (EN) (959.88 KB - PDF)

**First published:** 09/07/2009

**Last updated:** 09/07/2009

[View](/en/documents/assessment-report/sovrima-epar-public-assessment-report_en.pdf)

#### More information on Sovrima

- [EU/3/04/189 - orphan designation for treatment of Friedreich's ataxia](/en/medicines/human/orphan-designations/eu-3-04-189)

**This page was last updated on** 31/12/2009

## Share this page

[Back to top](#main-content)